Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ExcellGene, Cytovance Partner to Advance Biologics Development and Manufacture | Contract Pharma

What are you searching for?

Sign in
Breaking News

ExcellGene, Cytovance Partner to Advance Biologics Development and Manufacture

Will combine ExcellGene’s transposon technologies with Cytovance’s cGMP manufacturing expertise.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ExcellGene SA, a Swiss biotech service provider specializing in mammalian cell line development, has entered a strategic collaboration with Cytovance Biologics, a CDMO based in the U.S., to advance large molecule biologics development and manufacture.
 
Leveraging CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells for mammalian cell lines for recombinant protein production and biological research, this partnership aims to advance biopharmaceutical development by providing ExcellGene’s transposon technologies to Cytovance’s biopharma customers.
 
ExcellGene’s custom CHO and HEK cell lines can be used to optimize protein quality, quantity, development timelines, and scalability for biomanufacturing through custom engineering to the specific requirements of a protein. Combining these engineered cell lines with Cytovance’s cGMP manufacturing expertise, the companies expect to deliver a higher yield range of up to 10 g/L, to help customers advance their therapeutics from upstream development to clinical and commercial scale operations.
 
“We are thrilled to partner with Cytovance Biologics, a company that shares our commitment to excellence and innovation in biopharmaceutical manufacturing,” said Maria Wurm, CEO of ExcellGene SA. “Much like the team at Cytovance, I am proud to say that we have incredible experts in our company who are capable of mastering every challenge. Our top priority is to provide seamless services and cost-effective solutions tailormade for our clients’ needs.”
 
Stephanie Wickham, PhD, Senior Director of Technology at Cytovance, said, “Coupling our organizations’ respective 50+ years of experience in delivering solutions to the industry, we are very much looking forward to shepherding critical proteins expressed in one of ExcellGene’s exceptional host cell lines through process development and eventually, into our 2000L tanks. This partnership is part of our intentional effort to expand our ‘best of breed’ network and build a robust selection of cell and strain options so that our clients can always find the perfect fit for their target protein.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics